Paragonix Technologies will present new clinical findings on its liver and kidney preservation systems at the 2026 American Transplant Congress in Boston. The data, from multi-center clinical registries, highlight the benefits of Paragonix's controlled hypothermic preservation devices in improving transplant outcomes and expanding organ access. The company will also host a symposium discussing innovations in organ preservation and patient care throughout the transplant process. This event underscores Paragonix's commitment to advancing transplant technology and improving patient outcomes worldwide.
Bank7 Corp., the parent company of Bank7 based in Oklahoma City, announced a quarterly cash dividend of $0.27 per share on its common stock. The dividend will be paid on July 7, 2026, to shareholders of record as of June 19, 2026. Bank7 operates twel...
Scilex Holding Company announced that its board has set June 15, 2026, as the payment date for a previously declared dividend of Semnur Pharmaceuticals common stock to Scilex shareholders. The record date for eligibility is June 1, 2026, and sharehol...
U.S. stock futures showed mixed signals with S&P 500 futures down and Dow Jones up amid political tensions as the House passed a resolution limiting President Trump's military powers. Key stocks like Broadcom and CrowdStrike saw notable moves, with C...
Morgan Stanley predicts Apple's stock could rise significantly after the Worldwide Developers Conference (WWDC) if the company unveils major AI improvements, especially for Siri and Apple Intelligence. The bank highlights Apple's privacy focus and pa...
Broadcom reported strong Q2 results with $22.2 billion revenue and 143% growth in AI semiconductor revenue to $10.8 billion, beating expectations. However, the stock fell 15% due to cautious Q3 AI revenue guidance of $16 billion, below analyst estima...
